NO307513B1 - 2,8-disubstituert chinazolinon og anvendelse derav - Google Patents

2,8-disubstituert chinazolinon og anvendelse derav

Info

Publication number: NO307513B1
Authority: NO; Norway
Prior art keywords: quinazolinone; disubstituted; disubstituted quinazolinone
Prior art date: 1995-01-19

Application number

NO960222A

Other languages

English (en)

Other versions

NO960222D0 (no

NO960222L (no

Inventor

Fred Robert Heiker

Ulrich Niewoehner

Wolfgang Hartwig

Helmuth Schuetz

Erwin Bischoff

Elisabeth Perzborn

Matthias Schramm

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-19

Filing date

1996-01-18

Publication date

2000-04-17

1996-01-18 Application filed by Bayer Ag filed Critical Bayer Ag

1996-01-18 Publication of NO960222D0 publication Critical patent/NO960222D0/no

1996-07-22 Publication of NO960222L publication Critical patent/NO960222L/no

2000-04-17 Publication of NO307513B1 publication Critical patent/NO307513B1/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3

NO960222A 1995-01-19 1996-01-18 2,8-disubstituert chinazolinon og anvendelse derav NO307513B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19501481A DE19501481A1 (de)	1995-01-19	1995-01-19	2,8-Disubstituierte Chinazolinone

Publications (3)

Publication Number	Publication Date
NO960222D0 NO960222D0 (no)	1996-01-18
NO960222L NO960222L (no)	1996-07-22
NO307513B1 true NO307513B1 (no)	2000-04-17

Family

ID=7751829

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO960222A NO307513B1 (no)	1995-01-19	1996-01-18	2,8-disubstituert chinazolinon og anvendelse derav

Country Status (32)

Country	Link
US (1)	US5721238A (no)
EP (1)	EP0722937A1 (no)
JP (1)	JPH08253457A (no)
KR (1)	KR960029325A (no)
CN (1)	CN1134417A (no)
AR (1)	AR006738A1 (no)
AU (1)	AU704102B2 (no)
BG (1)	BG100293A (no)
BR (1)	BR9600148A (no)
CA (1)	CA2167345A1 (no)
CO (1)	CO4700522A1 (no)
CZ (1)	CZ16796A3 (no)
DE (1)	DE19501481A1 (no)
EE (1)	EE9600019A (no)
FI (1)	FI960227A (no)
HR (1)	HRP960004A2 (no)
HU (1)	HUP9600114A3 (no)
IL (1)	IL116770A (no)
IN (1)	IN184956B (no)
MA (1)	MA23780A1 (no)
NO (1)	NO307513B1 (no)
NZ (1)	NZ280831A (no)
PE (1)	PE66696A1 (no)
PL (1)	PL312352A1 (no)
RO (1)	RO117451B1 (no)
RU (1)	RU2158733C2 (no)
SG (1)	SG34377A1 (no)
SK (1)	SK7796A3 (no)
SV (1)	SV1996000005A (no)
TR (1)	TR199600029A2 (no)
YU (1)	YU1496A (no)
ZA (1)	ZA96397B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2238283C (en)	1997-05-30	2002-08-20	Cell Pathways, Inc.	Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) *	1997-05-30	1999-01-12	Cell Pathways, Inc.	Method for identifying compounds for inhibition of cancerous lesions
US20020025969A1 (en) *	1997-07-09	2002-02-28	Wolf-Georg Forssmann	Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6410584B1 (en)	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
US6132757A (en)	1998-05-01	2000-10-17	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6194433B1 (en) *	1998-10-05	2001-02-27	Neal R. Cutler	Sexual dysfunction in females
US6110489A (en) *	1998-05-01	2000-08-29	Cutler; Neal R.	Use of quinolines and quinolones to treat male erectile dysfunction
US6132753A (en) *	1998-05-01	2000-10-17	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en)	2000-06-19	2002-07-30	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en)	1999-03-04	2001-02-13	Neal R. Cutler	Use of cilostazol for treatment of sexual dysfunction
US6130053A (en) *	1999-08-03	2000-10-10	Cell Pathways, Inc.	Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) *	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) *	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en)	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) *	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6303135B1 (en)	1999-07-08	2001-10-16	Neal R. Cutler	Use of quinolines and quinolones to treat male erectile dysfunction
US6555547B1 (en)	2000-02-28	2003-04-29	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en)	2000-03-03	2003-05-27	Cell Pathways, Inc	Method for screening compounds for the treatment of neoplasia
US7501409B2 (en) *	2000-09-06	2009-03-10	Mitsubishi Tanabe Pharma Corporation	Preparations for oral administration
US6562838B2 (en) *	2001-01-26	2003-05-13	R. T. Alamo Ventures I, L.L.C.	Treatment of cardiovascular disease with quinolinone enantiomers
NZ527585A (en)	2001-02-15	2005-04-29	Tanabe Seiyaku Co	Tablets quickly disintegrated in oral cavity
CA2462149C (en) *	2001-11-30	2010-06-22	Pfizer Products Inc.	Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003250701A1 (en)	2002-07-31	2004-02-16	Wayne R. Danter	Protein tyrosine kinase inhibitors
ES2298563T3 (es)	2002-10-09	2008-05-16	Critical Outcome Technologies, Inc.	Inhibidores de proteinas tirosina cinasas.
US7863428B2 (en)	2002-12-27	2011-01-04	Tibotec Bvba	Fluorogenic enzyme substrates and methods of preparation
CN100506802C (zh) *	2004-06-04	2009-07-01	中国科学院上海药物研究所	一类甲酰肽样受体-1调节剂、其制备方法和用途
AU2007303846B2 (en) *	2006-10-04	2011-03-10	Pfizer Products Inc.	Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
US8034815B2 (en)	2007-01-11	2011-10-11	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101429166B (zh) *	2007-11-07	2013-08-21	上海特化医药科技有限公司	喹唑啉酮衍生物及其制备方法和用途
EP2225226B1 (en)	2007-12-26	2016-08-17	Critical Outcome Technologies, Inc.	Compounds and their use in a method for treatment of cancer
EP3239170B1 (en)	2008-06-04	2019-03-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2730890C (en)	2008-07-17	2018-05-15	Critical Outcome Technologies Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2745694C (en)	2008-12-03	2018-03-27	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase c agonists and methods of use
EP3235818A3 (en)	2010-04-01	2018-03-14	Critical Outcome Technologies, Inc.	Compounds for the treatment of hiv
EP2621509A4 (en)	2010-09-15	2016-08-03	Synergy Pharmaceuticals Inc	PREPARATIONS OF GUANYLATE CYCLASE-C AGONISTS AND METHODS OF USE
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) *	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP3097088A4 (en) *	2014-01-23	2017-10-04	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Icariin derivatives
ES2749433T3 (es)	2014-06-23	2020-03-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
CN110590769B (zh) *	2019-06-13	2021-09-24	中山大学	一对喹唑啉酮生物碱对映体及其制备方法和应用
WO2024026424A1 (en) *	2022-07-27	2024-02-01	Black Diamond Therapeutics, Inc.	Quinazolinone derivatives as and related uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3169129A (en) *	1963-05-10	1965-02-09	American Cyanamid Co	2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US4431440A (en) *	1981-02-20	1984-02-14	American Cyanamid Company	Method to alter or control the development and/or the life cycle of various plant species
GB9126260D0 (en) *	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
US5294612A (en) *	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

1995
- 1995-01-19 DE DE19501481A patent/DE19501481A1/de not_active Withdrawn
- 1995-12-26 IN IN2408DE1995 patent/IN184956B/en unknown
1996
- 1996-01-05 HR HR19501481.2A patent/HRP960004A2/hr not_active Application Discontinuation
- 1996-01-08 EP EP96100154A patent/EP0722937A1/de not_active Withdrawn
- 1996-01-11 US US08/584,865 patent/US5721238A/en not_active Expired - Fee Related
- 1996-01-12 YU YU1496A patent/YU1496A/sh unknown
- 1996-01-15 TR TR96/00029A patent/TR199600029A2/xx unknown
- 1996-01-15 AU AU40980/96A patent/AU704102B2/en not_active Ceased
- 1996-01-16 CA CA002167345A patent/CA2167345A1/en not_active Abandoned
- 1996-01-16 IL IL11677096A patent/IL116770A/xx active IP Right Grant
- 1996-01-16 NZ NZ280831A patent/NZ280831A/en unknown
- 1996-01-16 RO RO96-00077A patent/RO117451B1/ro unknown
- 1996-01-17 FI FI960227A patent/FI960227A/fi unknown
- 1996-01-17 JP JP8022973A patent/JPH08253457A/ja active Pending
- 1996-01-17 PL PL96312352A patent/PL312352A1/xx unknown
- 1996-01-17 SG SG1996000263A patent/SG34377A1/en unknown
- 1996-01-18 NO NO960222A patent/NO307513B1/no unknown
- 1996-01-18 BR BR9600148A patent/BR9600148A/pt active Search and Examination
- 1996-01-18 ZA ZA96397A patent/ZA96397B/xx unknown
- 1996-01-18 EE EE9600019A patent/EE9600019A/xx unknown
- 1996-01-18 BG BG100293A patent/BG100293A/xx unknown
- 1996-01-18 RU RU96100854/04A patent/RU2158733C2/ru active
- 1996-01-18 KR KR1019960001004A patent/KR960029325A/ko not_active Application Discontinuation
- 1996-01-18 SK SK77-96A patent/SK7796A3/sk unknown
- 1996-01-18 CZ CZ96167A patent/CZ16796A3/cs unknown
- 1996-01-18 MA MA24135A patent/MA23780A1/fr unknown
- 1996-01-19 PE PE1996000044A patent/PE66696A1/es not_active Application Discontinuation
- 1996-01-19 AR ARP960101087A patent/AR006738A1/es unknown
- 1996-01-19 SV SV1996000005A patent/SV1996000005A/es unknown
- 1996-01-19 CO CO96002168A patent/CO4700522A1/es unknown
- 1996-01-19 CN CN96101906A patent/CN1134417A/zh active Pending
- 1996-01-19 HU HU9600114A patent/HUP9600114A3/hu unknown

Also Published As

Publication number	Publication date
BR9600148A (pt)	1998-01-06
SG34377A1 (en)	1996-12-06
DE19501481A1 (de)	1996-07-25
IL116770A (en)	2000-08-31
AR006738A1 (es)	1999-09-29
US5721238A (en)	1998-02-24
MA23780A1 (fr)	1996-10-01
CN1134417A (zh)	1996-10-30
JPH08253457A (ja)	1996-10-01
EE9600019A (et)	1996-08-15
NO960222D0 (no)	1996-01-18
SV1996000005A (es)	1997-03-11
KR960029325A (ko)	1996-08-17
PE66696A1 (es)	1997-03-09
CZ16796A3 (en)	1996-08-14
YU1496A (sh)	1998-09-18
HUP9600114A2 (en)	1996-12-30
FI960227A (fi)	1996-07-20
RO117451B1 (ro)	2002-03-29
AU704102B2 (en)	1999-04-15
PL312352A1 (en)	1996-07-22
CA2167345A1 (en)	1996-07-20
RU2158733C2 (ru)	2000-11-10
NO960222L (no)	1996-07-22
HUP9600114A3 (en)	2000-03-28
IL116770A0 (en)	1996-05-14
TR199600029A2 (tr)	1996-08-21
NZ280831A (en)	1996-10-28
IN184956B (no)	2000-10-07
AU4098096A (en)	1996-07-25
HU9600114D0 (en)	1996-03-28
SK7796A3 (en)	1996-08-07
CO4700522A1 (es)	1998-12-29
ZA96397B (en)	1996-08-28
FI960227A0 (fi)	1996-01-17
BG100293A (en)	1996-07-31
EP0722937A1 (de)	1996-07-24
HRP960004A2 (en)	1998-02-28

Publication	Publication Date	Title
NO307513B1 (no)	2000-04-17	2,8-disubstituert chinazolinon og anvendelse derav
DK0823900T3 (da)	2001-04-02	Quinazolinderivater
DK0817775T3 (da)	2001-11-19	Quinazolinderivater
NO972236D0 (no)	1997-05-15	Dihydropyrimidiner og anvendelse derav
NO961425D0 (no)	1996-04-11	1N-alkyl-N-arylpyrimidinaminer og derivater derav
DE69432125D1 (de)	2003-03-20	Geldprüfer
DK0804078T3 (da)	2000-04-10	Sammensætning og anvendelse deraf
DK0639932T3 (da)	2002-04-22	Ørehænger
DE59505590D1 (de)	1999-05-12	Schmuckstück
IT1290381B1 (it)	1998-12-03	Azocomposti basici, loro produzioni ed utilizzo
NO991123D0 (no)	1999-03-08	25-metylen- og 24,25-epoksy-marcfortiner og paraherkamider
KR970015954U (ko)	1997-05-23	길이조절이 가능한 팔찌
KR970026683U (ko)	1997-07-24	가변형 팔찌
DE69521119D1 (de)	2001-07-05	Schmuck- oder juwelierware
DE69637431D1 (de)	2008-03-27	Ungen und ihre verwendung
IT240461Y1 (it)	2001-04-02	Braccialetto ad ampiezza regolabile
NO954481D0 (no)	1995-11-08	Smykke
SE9504421D0 (sv)	1995-12-11	Kombinationssmycke
KR980000326U (ko)	1998-03-30	귀걸이
DK134193D0 (da)	1993-12-01	Personvender
FIU930553U0 (fi)	1993-11-18	Skenarier foer en person
FI931273A (fi)	1994-09-24	Korvakoru
KR970010883U (ko)	1997-03-29	시간조절이 가능한 생활 시간표
KR960003744U (ko)	1996-02-14	귀걸이
KR970016362U (ko)	1997-05-23	전동체